In vivo Tumor Models

In vivo tumor xenograft models, including CDX, PDX, syngeneic hPBMC, HSC, immune checkpoint

WuXi Biology has significant experience in oncology drug discovery. We offer a large collection of tumors models for small and large molecule drug development, including:

  • Cell line-derived xenograft (CDX) tumor models
  • Patient-derived xenograft (PDX) tumor models
  • Syngeneic tumor models
  • Human immune checkpoint gene KI mouse models
  • hPBMC/HSC humanized models

Cell line-derived xenograft (CDX) tumor models

immunology, oncology, immuno-oncology

41 luciferase labeled orthotopic/metastatic tumor models

tumor, t cells
  • Covering 17 tumor types
  • Bioluminescent imaging system
  • Specific-pathogen-free (SPF) barrier

Patient-derived xenograft (PDX) tumor models

T cells, cancer cells

Syngeneic tumor models

T cells, cancer cell

hPBMC/HSC humanized models

hPBMC Humanized Models

  • Established models for immune-checkpoint inhibitor and bi-specific antibody candidates in a human-resembling immune system.
  • Annotation for both immune cells (phenotyping, biomarker, functions) and tumor cells (expression, mutation)
  • Different PBMC delivery systems (systemic injection or co-inoculation with tumor)

HSC Humanized Models

  • Available humanized models from CIEA combined with WuXi PDX/CDX models.
  • Customizable with human cytokine transgenic mice (GM-CSF/hIL-3 or hIL-2) to improve the reconstitution of myeloid lineage.

Established CDX/PDX-hPBMC Models


Genetically engineered models

  • 48 engineered cell lines based on construct overexpression or gene knock-in
  • Pharmacologically validated in vitro and in vivo
  • Focusing at drug-resistant mutation introduction and IO-related checkpoint humanization
  • Example targets: EGFR, ROS1, ALK, RET, FLT3, BTK, Claudin18.2, PD-L1

Human immune checkpoint gene KI mouse models

KI (Knock-in) mice offer the possibility to study checkpoint antibodies targeting human checkpoints in the context of a fully functional immune system.

  • Collection of various targets and background mouse strains
  • Validated with launched or most advanced clinical grade checkpoint antibodies
  • Double checkpoint KI mice customizable for combination (PD1 + OX40, PD1 + TIM3)
Human immune checkpoint gene knock-in KI mouse models, PD-1, CTLA-4
Human immune checkpoint gene knock-in KI mouse models, PD-1, CTLA-4, CD137

Related Resources View All

Targeted Protein Degradation of Mutant ER-alpha

Resource Type: Latest Science Presentation

siRNA Efficacy in a Xenograft Tumor Model

Resource Type: Latest Science Presentation

Paclitaxel-Resistant Tumor Models

Resource Type: Latest Science Presentation

NK Cell Humanized Tumor Models

Resource Type: Latest Science Presentation